Cofttek holdings limited

Wnt&Beta catenin

BML-284 (853220-52-7)

BML-284 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Not Intended for Therapeutic Use. For research use only.

CAS: 853220-52-7 Category

BML-284 (853220-52-7) Description

BML-284 HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

BML-284, also known as AMBMP and Wnt agonist 1, is a potent and selective activator of Wnt signaling. It enhances beta-catenin and increases transcript and protein levels of p-gp.

 

BML-284 (853220-52-7) Specifications

Product Name BML-284
Synonym  AMBMP HCl; AMBMP Hydrochloride; BML284 HCl; Wnt Agonist; BML284 HCl; BML-284 HCl; BML 284 HCl;
Chemical Name  4-N-(1,3-Benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Hydrochloride
Drug Class N/A
Purity ≥ >98%
CAS Number  853220-52-7
Molecular Formula  C19H19ClN4O3
Molecular Weight 386.84
Monoisotopic Mass 396.16986
MDL number SML0795
InChIKey XZOFNDFDGVAIEH-UHFFFAOYSA-N
InChi Code  InChI=1S/C19H18N4O3.ClH/c1-24-14-4-2-3-13(8-14)15-9-18(23-19(20)22-15)21-10-12-5-6-16-17(7-12)26-11-25-16;/h2-9H,10-11H2,1H3,(H3,20,21,22,23);1H
SMILES  NC1=NC(C2=CC=CC(OC)=C2)=CC(NCC3=CC=C(OCO4)C4=C3)=N1.[H]Cl
Form  PF670462
Color N/A
Solubility  Soluble in DMSO
Storage Temp.  0 – 4 C for short term (days to weeks), or -20 C for long term (months).
Shelf life > >2 years if stored properly
Handling SDS
Application In preparation of a product treating polycystic kidney disease is disclosed

 


=

RIDADR NONH for all modes of transport

References:

[1]. Guimaraes PPG, Tan M, Tammela T, Wu K, Chung A, Oberli M, Wang K, Spektor R, Riley RS, Viana CTR, Jacks T, Langer R, Mitchell MJ. J Control Release. 2018 Nov 28;290:75-87. doi: 10.1016/j.jconrel.2018.09.025. Epub 2018 Oct 2.

[2]. Yang JM, Huang HM, Cheng JJ, Huang CL, Lee YC, Chiou CT, Huang HT, Huang NK, Yang YC. Toxicology. 2018 Dec 1;410:65-72. doi: 10.1016/j.tox.2018.09.003. Epub 2018 Sep 8.

[3]. Suwala AK, Koch K, Rios DH, Aretz P, Uhlmann C, Ogorek I, Felsberg J, Reifenberger G, Köhrer K, Deenen R, Steiger HJ, Kahlert UD, Maciaczyk J. Oncotarget. 2018 Apr 27;9(32):22703-22716. doi: 10.18632/oncotarget.25210. eCollection 2018 Apr 27.

[4].Madan B, McDonald MJ, Foxa GE, Diegel CR, Williams BO, Virshup DM. Bone Res. 2018 May 25;6:17. doi: 10.1038/s41413-018-0017-8. eCollection 2018.

[5]. Funck-Brentano T, Nilsson KH, Brommage R, Henning P, Lerner UH, Koskela A, Tuukkanen J, Cohen-Solal M, Movérare-Skrtic S, Ohlsson C. J Endocrinol. 2018 Jul;238(1):13-23. doi: 10.1530/JOE-18-0153. Epub 2018 May 2.